Cargando…

局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告

BACKGROUND AND OBJECTIVE: Controversies exists with regard to target volumes as far as thoracic radiotherapy (TRT) is concerned in the multimodality treatment for limited-stage small cell lung cancer (LSCLC). The aim of this study is to prospectively compare the local control rate, toxicity profiles...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000379/
https://www.ncbi.nlm.nih.gov/pubmed/20673485
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.07.07
_version_ 1783331704400773120
collection PubMed
description BACKGROUND AND OBJECTIVE: Controversies exists with regard to target volumes as far as thoracic radiotherapy (TRT) is concerned in the multimodality treatment for limited-stage small cell lung cancer (LSCLC). The aim of this study is to prospectively compare the local control rate, toxicity profiles, and overall survival (OS) between patients received different target volumes irradiation after induction chemotherapy. METHODS: LSCLC patients received 2 cycles of etoposide and cisplatin (EP) induction chemotherapy and were randomly assigned to receive TRT to either the postor pre-chemotherapy tumor extent (GTV-T) as study arm and control arm, CTV-N included the positive nodal drainage area for both arms. One to 2 weeks after induction chemotherapy, 45 Gy/30 Fx/19 d TRT was administered concurrently with the third cycle of EP regimen. After that, additional 3 cycles of EP consolidation were administered. Prophylactic cranial irradiation (PCI) was administered to patients with a complete response. RESULTS: Thirty-seven and 40 patients were randomly assigned to study arm and control arm. The local recurrence rates were 32.4% and 28.2% respectively (P=0.80); the isolated nodal failure (INF) rates were 3.0% and 2.6% respectively (P=0.91); all INF sites were in the ipsilateral supraclavicular fossa. Medastinal N3 disease was the risk factor for INF (P=0.02, OR=14.13, 95%CI: 1.47-136.13). During radiotherapy, grade Ⅰ, Ⅱ weight loss was observed in 29.4%, 5.9% and 56.4%, 7.7% patients respectively (P=0.04). Grade 0-Ⅰ and Ⅱ-Ⅲ late pulmonary injury was developed in 97.1%, 2.9% and 86.4%, 15.4% patients respectively (P=0.07). Median survival time was 22.1 months and 26.9 months respectively. The 1 to 3-year OS were 77.9%, 44.4%, 37.3% and 75.8%, 56.3%, 41.7% respectively (P=0.79). CONCLUSION: The preliminary results of this study indicate that irradiant the post-chemotherapy tumor extent (GTV-T) and positive nodal drainage area did not decrease local control and overall survival while radiation toxicity was reduced. But the current sample size has not met designed requirements, and further investigation is warranted before final conclusions could be drawn.
format Online
Article
Text
id pubmed-6000379
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60003792018-07-06 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Controversies exists with regard to target volumes as far as thoracic radiotherapy (TRT) is concerned in the multimodality treatment for limited-stage small cell lung cancer (LSCLC). The aim of this study is to prospectively compare the local control rate, toxicity profiles, and overall survival (OS) between patients received different target volumes irradiation after induction chemotherapy. METHODS: LSCLC patients received 2 cycles of etoposide and cisplatin (EP) induction chemotherapy and were randomly assigned to receive TRT to either the postor pre-chemotherapy tumor extent (GTV-T) as study arm and control arm, CTV-N included the positive nodal drainage area for both arms. One to 2 weeks after induction chemotherapy, 45 Gy/30 Fx/19 d TRT was administered concurrently with the third cycle of EP regimen. After that, additional 3 cycles of EP consolidation were administered. Prophylactic cranial irradiation (PCI) was administered to patients with a complete response. RESULTS: Thirty-seven and 40 patients were randomly assigned to study arm and control arm. The local recurrence rates were 32.4% and 28.2% respectively (P=0.80); the isolated nodal failure (INF) rates were 3.0% and 2.6% respectively (P=0.91); all INF sites were in the ipsilateral supraclavicular fossa. Medastinal N3 disease was the risk factor for INF (P=0.02, OR=14.13, 95%CI: 1.47-136.13). During radiotherapy, grade Ⅰ, Ⅱ weight loss was observed in 29.4%, 5.9% and 56.4%, 7.7% patients respectively (P=0.04). Grade 0-Ⅰ and Ⅱ-Ⅲ late pulmonary injury was developed in 97.1%, 2.9% and 86.4%, 15.4% patients respectively (P=0.07). Median survival time was 22.1 months and 26.9 months respectively. The 1 to 3-year OS were 77.9%, 44.4%, 37.3% and 75.8%, 56.3%, 41.7% respectively (P=0.79). CONCLUSION: The preliminary results of this study indicate that irradiant the post-chemotherapy tumor extent (GTV-T) and positive nodal drainage area did not decrease local control and overall survival while radiation toxicity was reduced. But the current sample size has not met designed requirements, and further investigation is warranted before final conclusions could be drawn. 中国肺癌杂志编辑部 2010-07-20 /pmc/articles/PMC6000379/ /pubmed/20673485 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.07.07 Text en 版权所有©《中国肺癌杂志》编辑部2010 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
title 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
title_full 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
title_fullStr 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
title_full_unstemmed 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
title_short 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
title_sort 局限期小细胞肺癌放疗靶区前瞻性随机对照研究的初步报告
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000379/
https://www.ncbi.nlm.nih.gov/pubmed/20673485
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.07.07
work_keys_str_mv AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào
AT júxiànqīxiǎoxìbāofèiáifàngliáobǎqūqiánzhānxìngsuíjīduìzhàoyánjiūdechūbùbàogào